JPH0920661A - Learning ability-improving composition - Google Patents
Learning ability-improving compositionInfo
- Publication number
- JPH0920661A JPH0920661A JP7168749A JP16874995A JPH0920661A JP H0920661 A JPH0920661 A JP H0920661A JP 7168749 A JP7168749 A JP 7168749A JP 16874995 A JP16874995 A JP 16874995A JP H0920661 A JPH0920661 A JP H0920661A
- Authority
- JP
- Japan
- Prior art keywords
- methylhistidine
- anserine
- carnosine
- food
- drink
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 claims abstract description 83
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 claims abstract description 83
- 108010085443 Anserine Proteins 0.000 claims abstract description 82
- 241000210053 Potentilla elegans Species 0.000 claims abstract description 82
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims abstract description 81
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims abstract description 80
- 108010087806 Carnosine Proteins 0.000 claims abstract description 79
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims abstract description 78
- 229940044199 carnosine Drugs 0.000 claims abstract description 78
- -1 imidazole compound Chemical class 0.000 claims abstract description 56
- 235000013305 food Nutrition 0.000 claims abstract description 51
- BRMWTNUJHUMWMS-LURJTMIESA-N N(tele)-methyl-L-histidine Chemical compound CN1C=NC(C[C@H](N)C(O)=O)=C1 BRMWTNUJHUMWMS-LURJTMIESA-N 0.000 claims abstract description 47
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 claims abstract description 43
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims abstract description 40
- 230000000694 effects Effects 0.000 claims abstract description 20
- 235000013376 functional food Nutrition 0.000 claims abstract description 15
- 150000002460 imidazoles Chemical class 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 8
- 239000000284 extract Substances 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 3
- 230000003340 mental effect Effects 0.000 abstract description 10
- 241000555825 Clupeidae Species 0.000 abstract description 4
- 230000002708 enhancing effect Effects 0.000 abstract description 4
- 235000019512 sardine Nutrition 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 235000013361 beverage Nutrition 0.000 abstract description 2
- SLRNWACWRVGMKD-QMMMGPOBSA-N Balenine Chemical compound CN1C=NC(C[C@H](N=C(O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-QMMMGPOBSA-N 0.000 abstract 1
- 108010084730 N(beta)-alanyl-1-methyl-histidine Proteins 0.000 abstract 1
- 241000269821 Scombridae Species 0.000 abstract 1
- 239000012141 concentrate Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000003014 reinforcing effect Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 16
- 150000003839 salts Chemical class 0.000 description 13
- 206010016256 fatigue Diseases 0.000 description 12
- 208000019914 Mental Fatigue Diseases 0.000 description 11
- 241000287828 Gallus gallus Species 0.000 description 9
- 235000013330 chicken meat Nutrition 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 235000013372 meat Nutrition 0.000 description 8
- 230000036651 mood Effects 0.000 description 7
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000015654 memory Effects 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 235000019511 tuna Nutrition 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 235000015277 pork Nutrition 0.000 description 4
- 235000013580 sausages Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 3
- 241000283153 Cetacea Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- CYZKJBZEIFWZSR-LURJTMIESA-N N(alpha)-methyl-L-histidine Chemical compound CN[C@H](C(O)=O)CC1=CNC=N1 CYZKJBZEIFWZSR-LURJTMIESA-N 0.000 description 3
- 241000270295 Serpentes Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 235000008429 bread Nutrition 0.000 description 3
- 125000002843 carboxylic acid group Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 235000019688 fish Nutrition 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000006403 short-term memory Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000269851 Sarda sarda Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000000561 anti-psychotic effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000003028 elevating effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000021056 liquid food Nutrition 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000269819 Katsuwonus pelamis Species 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- YBHQCJILTOVLHD-YVMONPNESA-N Mirin Chemical compound S1C(N)=NC(=O)\C1=C\C1=CC=C(O)C=C1 YBHQCJILTOVLHD-YVMONPNESA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 235000015241 bacon Nutrition 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 150000002410 histidine derivatives Chemical class 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 150000002506 iron compounds Chemical class 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 235000019992 sake Nutrition 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- IUWLTSZHVYHOHY-FJXQXJEOSA-L zinc;(2s)-2-(3-azanidylpropanoylazanidyl)-3-(1h-imidazol-5-yl)propanoate Chemical class [Zn+2].[NH-]CCC(=O)[N-][C@H](C([O-])=O)CC1=CN=CN1 IUWLTSZHVYHOHY-FJXQXJEOSA-L 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、アンセリン、カル
ノシン、バレニン、π−メチルヒスチジン、又はτ−メ
チルヒスチジンを有効成分とする医薬品又は機能性食品
の組成物、並びにアンセリン、カルノシン、バレニン、
π−メチルヒスチジン及びτ−メチルヒスチジンを実質
上含有しない飲食物に、アンセリン、カルノシン、バレ
ニン、π−メチルヒスチジン及びτ−メチルヒスチジン
の群から選ばれた1種以上のイミダゾール化合物、又は
これを主成分とする抽出物を添加してなる新規な飲食
品、及びその製造方法に関するものである。TECHNICAL FIELD The present invention relates to a composition of a medicine or a functional food containing anserine, carnosine, valenin, π-methylhistidine, or τ-methylhistidine as an active ingredient, and anserine, carnosine, valenin,
Foods and drinks that do not substantially contain π-methylhistidine and τ-methylhistidine, one or more imidazole compounds selected from the group of anserine, carnosine, varenin, π-methylhistidine and τ-methylhistidine, or mainly these. The present invention relates to a novel food or drink product to which an extract as a component is added, and a method for producing the same.
【0002】[0002]
【従来の技術】様々な精神的活動を行ううえで生じてく
る精神的疲労感は、頭脳作業の能率を下げ、かつ作業の
正確さを著しく損ねることが知られている。近年、産業
界において第三次産業に従事する人口が大きな割合を占
めるようになり精神的疲労感を抱きやすい業務に携わる
人々が増えたこと、及び学習機会の増加等によって恒常
的な精神疲労感を抱く若年層が増えたこと等が大きな問
題となっている。2. Description of the Related Art It is known that the feeling of mental fatigue that occurs when performing various mental activities reduces the efficiency of brain work and significantly impairs the accuracy of work. In recent years, the number of people engaged in tertiary industry has become large in the industrial world, and the number of people who are engaged in work that is prone to mental fatigue has increased. The increase in the number of young people who have a hut is a big problem.
【0003】このような背景において、覚醒剤や麻薬の
ような危険な薬物を用いて、精神疲労を軽減する人々が
増えていることも大きな社会問題となっている。精神活
動によって生じる疲労感を軽減することによって意識の
高揚をはかり、集中力を増強し、頭脳作業の能率や正確
さを改善し、学習能力を向上させうる安全な薬剤又は飲
食品はこれまで開発されておらず、強く望まれていた。Against this background, the increase in the number of people who reduce mental fatigue by using dangerous drugs such as stimulants and narcotics has become a big social problem. To date, we have developed safe drugs or foods and drinks that can improve consciousness, enhance concentration, improve brain work efficiency and accuracy, and improve learning ability by reducing fatigue caused by mental activity. It was not done and was strongly desired.
【0004】一方、アンセリン(β−アラニル−π−メ
チル−L−ヒスチジン)、カルノシン(β−アラニル−
L−ヒスチジン)及びバレニン(β−アラニル−τ−メ
チル−L−ヒスチジン)は、哺乳類、鳥類、爬虫類、両
生類などの筋肉組織中に存在するジペプチドであり、既
に公知の物質である。また、π−メチルヒスチジン及び
τ−メチルヒスチジンは、それぞれアンセリン及びバレ
ニンの生合成中間体として知られている。On the other hand, anserine (β-alanyl-π-methyl-L-histidine), carnosine (β-alanyl-
L-histidine) and varenin (β-alanyl-τ-methyl-L-histidine) are dipeptides existing in muscle tissues of mammals, birds, reptiles, amphibians, etc., and are already known substances. Further, π-methylhistidine and τ-methylhistidine are known as biosynthetic intermediates of anserine and valenin, respectively.
【0005】これらのジペプチドが今世紀はじめに発見
されて以来、多くの研究がなされ、アンセリンやバレニ
ンは脊椎動物の骨格筋中に1−20mMの濃度範囲で存在
することが報告されている。その含量は筋肉の種類や動
物の年齢とともに変化することが知られているが、その
生理作用については未だ完全には明らかになっていな
い。Since the discovery of these dipeptides at the beginning of this century, many studies have been conducted, and it has been reported that anserine and valenin are present in skeletal muscles of vertebrates in a concentration range of 1-20 mM. Its content is known to change with the type of muscle and the age of the animal, but its physiological action has not been completely clarified yet.
【0006】しかしながら、近年になり作用効果の研究
が行われ、特開平1−246218号公報では、L−ア
ンセリンが免疫調節作用を有することが、特開平4−1
6166号公報にはカルノシン、アンセリン及びバレニ
ンの血圧上昇抑制作用を有することが、特公平4−62
299号公報では、カルノシン亜鉛塩が肝障害の予防、
治療剤として有用であることが、また文献(日本生理誌
(1990)52,221−228)には、L−カルノ
シンの肝機能保護作用とストレス関連物質の代謝促進作
用が開示されている。[0006] However, in recent years, research on the action and effect has been conducted, and in JP-A-1-246218, L-anserin has an immunomodulatory action.
Japanese Patent Publication No. 6-62 discloses that carnosine, anserine and varenin have a blood pressure elevation suppressing action.
In 299 publication, carnosine zinc salt prevents liver damage,
It is useful as a therapeutic agent, and the literature (Japanese Physiology (1990) 52, 221-228) discloses the liver function-protecting action of L-carnosine and the metabolism promoting action of stress-related substances.
【0007】さらに特開平4−187067号公報で
は、カルノシン、アンセリン及びバレニンがタンパク質
食品の酸化防止効果を有することが、特公昭63−47
435号公報では、カルノシン、アンセリン及びバレニ
ンを製品含有量で0.1%以上となるように添加し、か
つpHを6.5以上とすることにより製品の呈味を改善す
ることが開示されている。しかしながらアンセリン、カ
ルノシン、バレニン、π−メチルヒスチジン及びτ−メ
チルヒスチジンが学習能力の向上作用を有することは全
く知られていなかった。Further, in JP-A-4-187067, it is disclosed that carnosine, anserine and valenin have an antioxidant effect on protein foods.
Japanese Patent No. 435 discloses that carnosine, anserine, and valenin are added so that the product content is 0.1% or more, and the pH is 6.5 or more to improve the taste of the product. There is. However, it has not been known at all that anserine, carnosine, valenin, π-methylhistidine and τ-methylhistidine have a learning ability improving effect.
【0008】[0008]
【発明が解決しようとする課題】したがって、本発明
は、安全性の高い学習能力向上剤又は学習能力の向上作
用を有する機能性食品、並びにアンセリン、カルノシ
ン、バレニン、π−メチルヒスチジン及びτ−メチルヒ
スチジンを実質上含有しない飲食物に、アンセリン、カ
ルノシン、バレニン、π−メチルヒスチジン及びτ−メ
チルヒスチジンの群から選ばれた1種以上のイミダゾー
ル化合物、又はこれを主成分とする抽出物を添加してな
る新規な飲食品又は学習能力の向上作用を有する飲食品
を提供しようとするものである。Therefore, the present invention provides a highly safe learning ability improving agent or a functional food having an action of improving learning ability, as well as anserine, carnosine, varenin, π-methylhistidine and τ-methyl. To foods and drinks that do not substantially contain histidine, one or more imidazole compounds selected from the group of anserine, carnosine, varenin, π-methylhistidine and τ-methylhistidine, or an extract containing this as a main component is added. The present invention is intended to provide a new food or drink or a food or drink having an effect of improving learning ability.
【0009】[0009]
【課題を解決するための手段】本発明者らは、上記課題
を解決するため鋭意研究を行なった結果、アンセリン、
カルノシン、バレニン、π−メチルヒスチジン、τ−メ
チルヒスチジンが、過度の精神活動によって生じる疲労
感を予防又は軽減し、意識を高揚し、集中力を増強し、
学習能力における作業の能率及び正確さを改善する効果
を示すことを見い出し、本発明を完成させるに至った。
したがって本発明は、アンセリン、カルノシン、バレニ
ン、π−メチルヒスチジン及びτ−メチルヒスチジンの
群から選ばれた1種以上のイミダゾール化合物を含有し
てなる学習能力向上組成物を提供しようとするものであ
る。Means for Solving the Problems As a result of earnest research to solve the above problems, the present inventors have found that anserine,
Carnosine, valenin, π-methylhistidine, τ-methylhistidine prevent or reduce the feeling of fatigue caused by excessive mental activity, enhance consciousness, enhance concentration,
The inventors have found that they have the effect of improving the efficiency and accuracy of work in learning ability, and have completed the present invention.
Therefore, the present invention is intended to provide a learning ability improving composition comprising one or more imidazole compounds selected from the group of anserine, carnosine, valenin, π-methylhistidine and τ-methylhistidine. .
【0010】本発明はまた、アンセリン、カルノシン、
バレニン、π−メチルヒスチジン及びτ−メチルヒスチ
ジンを実質上含有しない飲食物に、アンセリン、カルノ
シン、バレニン、π−メチルヒスチジン及びτ−メチル
ヒスチジンの群から選ばれた1種以上のイミダゾール化
合物、又はこれを主成分とする抽出物を添加してなる新
規な飲食品又は学習能力の向上作用を有する飲食品に関
する。さらにアンセリン、カルノシン、バレニン、π−
メチルヒスチジン、及びτ−メチルヒスチジンを生来的
に実質上含有しない飲食物に、アンセリン、カルノシ
ン、バレニン、π−メチルヒスチジン、及びτ−メチル
ヒスチジン又はこれを主成分とする抽出物を添加するこ
とを特徴とする新規な飲食品又は学習能力の向上作用を
有する飲食品の製造方法に関する。The present invention also relates to anserine, carnosine,
Valenin, food and drink substantially free of π-methylhistidine and τ-methylhistidine, anserine, carnosine, varenin, one or more imidazole compounds selected from the group of π-methylhistidine and τ-methylhistidine, or this The present invention relates to a novel food or drink obtained by adding an extract containing as a main component or a food or drink having an action of improving learning ability. Furthermore, anserine, carnosine, valenin, π-
Methylhistidine, and τ-methylhistidine, to foods and drinks that do not substantially contain naturally, anserine, carnosine, valenin, π-methylhistidine, and τ-methylhistidine or to add an extract having a main component thereof. The present invention relates to a method for producing a novel food or drink or a food or drink having an effect of improving learning ability.
【0011】[0011]
【具体的な説明】本発明において使用するアンセリン、
カルノシン、バレニン、π−メチルヒスチジン及びτ−
メチルヒスチジンは、天然物、例えばカツオ節あるいは
煮干しの製造時に排出される煮汁や、マグロ缶詰の製造
時に排出される煮汁、あるいは廃鶏肉等の安価な原料か
ら抽出・分離・精製されたものであっても、化学的、酵
素的に合成されたものであっても、また微生物によって
産生されたものであってもよい。また本発明のアンセリ
ン、カルノシン、バレニン、π−メチルヒスチジン及び
τ−メチルヒスチジンはD体、L体、DL体のいずれで
あってもよい。なお天然に存在するアンセリン、カルノ
シン、バレニン、π−メチルヒスチジン及びτ−メチル
ヒスチジンは全てL体であるため、飲食品として使用す
る場合にはL体が好ましい。[Detailed Description] Anserine used in the present invention,
Carnosine, Valenin, π-Methylhistidine and τ-
Methylhistidine is a natural product, for example, broth discharged during the production of bonito flakes or dried sardines, broth discharged during the production of canned tuna, or is extracted, separated and purified from inexpensive raw materials such as waste chicken. However, it may be chemically or enzymatically synthesized, or may be produced by a microorganism. Further, the anserine, carnosine, varenin, π-methylhistidine and τ-methylhistidine of the present invention may be any of D-form, L-form and DL-form. Since naturally occurring anserine, carnosine, varenin, π-methylhistidine and τ-methylhistidine are all L-forms, the L-form is preferable when used as a food or drink.
【0012】本発明のアンセリン、カルノシン、バレニ
ン、π−メチルヒスチジン及びτ−メチルヒスチジン
は、塩の形であってもよく、アンセリン塩、カルノシン
塩、バレニン塩、π−メチルヒスチジン塩、τ−メチル
ヒスチジン塩としては、カルボン酸基に基づく塩と、ア
ミノ基に基づく、薬理学上許容される酸との酸付加塩が
あり、またカルボン酸基とアミノ基の双方に基づく塩が
ある。The anserine, carnosine, valenin, π-methylhistidine and τ-methylhistidine of the present invention may be in the form of a salt, such as anserine salt, carnosine salt, valenine salt, π-methylhistidine salt, τ-methylhistine. Histidine salts include salts based on carboxylic acid groups and acid addition salts based on amino groups and pharmacologically acceptable acids, and salts based on both carboxylic acid groups and amino groups.
【0013】カルボン酸基に基づく塩にはナトリウム、
カリウム、カルシウム、マグネシウム、亜鉛およびアル
ミニウムのような金属との塩、アンモニウム塩および置
換アンモニウム塩、例えばトリエチルアミンのようなト
リアルキルアミンその他のアミンとの塩があり、アミノ
基に基づく塩には塩酸、硫酸、リン酸、酢酸、プロピオ
ン酸、乳酸、酒石酸、クエン酸、コハク酸、マレイン
酸、ベンゼンスルホン酸、トルエンスルホン酸などの無
機酸、有機酸との塩があるが、これらはそれ自体、公知
の方法により、遊離のアンセリン、カルノシン、バレニ
ン、π−メチルヒスチジン、τ−メチルヒスチジンを化
学量論的に計算された量の、選択された酸または塩基と
反応させることによって製造することができる。またこ
れらは単独で又は組み合わせて使用することができる。Salts based on carboxylic acid groups include sodium,
There are salts with metals such as potassium, calcium, magnesium, zinc and aluminum, ammonium salts and substituted ammonium salts, for example salts with trialkylamines and other amines such as triethylamine, and salts based on amino groups include hydrochloric acid, There are salts with inorganic acids and organic acids such as sulfuric acid, phosphoric acid, acetic acid, propionic acid, lactic acid, tartaric acid, citric acid, succinic acid, maleic acid, benzenesulfonic acid and toluenesulfonic acid, which are known per se. Can be prepared by reacting free anserine, carnosine, varenin, π-methylhistidine, τ-methylhistidine with a stoichiometrically calculated amount of the selected acid or base. These may be used alone or in combination.
【0014】本発明において、本発明のアンセリン、カ
ルノシン、バレニン、π−メチルヒスチジン及びτ−メ
チルヒスチジンは、必ずしも高純度精製品に限ったこと
はなく、本発明のイミダゾール化合物を主成分とする抽
出物を使用することもできる。本発明のπ−メチルヒス
チジン又はτ−メチルヒスチジンは各々、アンセリン、
バレニンを構成するアミノ酸であり、アンセリンやバレ
ニンと同様の効果を有すると考える。In the present invention, the anserine, carnosine, valenin, π-methylhistidine and τ-methylhistidine of the present invention are not necessarily limited to high-purity purified products, and extraction using the imidazole compound of the present invention as a main component. The thing can also be used. The π-methylhistidine or τ-methylhistidine of the present invention is anserine,
It is an amino acid that constitutes valenin and is considered to have the same effect as anserine and valenin.
【0015】ここで本発明のイミダゾール化合物を主成
分とする抽出物とは、例えばカツオ節あるいは煮干しの
製造時に排出される煮汁や、マグロ缶詰の製造時に排出
される煮汁の濃縮液や鶏肉等から常法に従って抽出され
た抽出物、あるいはカツオ節あるいは煮干しの製造時に
排出される煮汁や、マグロ缶詰の製造時に排出される煮
汁等から常法に従って分離された本発明のイミダゾール
化合物を含有する画分等を挙げることができる。The extract containing the imidazole compound as a main component of the present invention means, for example, broth discharged during the production of bonito flakes or dried sardines, concentrated liquid of broth discharged during the production of canned tuna, chicken and the like. An extract extracted according to a conventional method, or a broth discharged during the production of skipjack tuna or dried sardines, or a fraction containing the imidazole compound of the present invention separated according to a conventional method from the broth discharged during the production of canned tuna Etc. can be mentioned.
【0016】特にマグロ缶詰の製造時に排出される煮汁
からの画分にはアンセリンやカルノシン、π−メチルヒ
スチジンが豊富に含まれているため好ましい。また鶏肉
等から常法に従って抽出された抽出物にはアンセリンと
カルノシンが豊富に含まれているため好ましい。なお本
発明のイミダゾール化合物を主成分とする抽出物のイミ
ダゾール化合物の含量は2%以上、好ましくは10%以
上、より好ましくは50%以上がよく、特にアンセリン
及び/又はカルノシンの含量は0.2%以上、好ましく
は1%以上、より好ましくは5%以上がよい。Particularly, the fraction from the broth discharged during the production of canned tuna is preferable because it contains abundant amounts of anserine, carnosine and π-methylhistidine. Further, the extract extracted from chicken or the like by a conventional method is preferable because it contains abundant amounts of anserine and carnosine. The content of the imidazole compound in the imidazole compound-based extract of the present invention is preferably 2% or more, preferably 10% or more, more preferably 50% or more, and particularly the anserine and / or carnosine content is 0.2. % Or more, preferably 1% or more, more preferably 5% or more.
【0017】本発明の学習能力向上組成物には、過度の
精神活動によって生じる疲労感を予防又は軽減し、集中
力を増強し、意識を高揚し、精神活動の能率及び正確さ
を改善することによって学習能力における作業の能率及
び正確さを改善する作用があり、従って本発明の化合物
は、学習能力を向上させる、あるいは精神疲労を予防
し、又は精神疲労からの回復を促進させる、意識を高揚
させる、集中力を増強させること等に有用であり、医薬
品又は機能性食品、飲食品として用いることができる。The learning ability-improving composition of the present invention prevents or reduces the feeling of fatigue caused by excessive mental activity, enhances concentration, raises consciousness, and improves the efficiency and accuracy of mental activity. Have the effect of improving the efficiency and accuracy of tasks in learning ability, and thus the compounds of the present invention enhance the ability to learn, prevent mental fatigue, or promote recovery from mental fatigue, which enhances consciousness. It is useful for, for example, enhancing the concentration, and can be used as a medicine, a functional food, or a food or drink.
【0018】本発明の学習能力向上組成物を医薬品とし
て用いる場合、投与形態は経口投与または非経口投与が
都合よく行われるものであればどのような剤形のもので
あってもよく、例えば注射液、輸液、散剤、顆粒剤、錠
剤、カプセル剤、腸溶剤、トローチ、内用液剤、懸濁
剤、乳剤、シロップ剤、外用液剤、湿布剤、点鼻剤、点
耳剤、点眼剤、吸入剤、軟膏剤、ローション剤、坐剤等
を挙げることができ、これらを症状に応じてそれぞれ単
独で、または組合わせて使用することができる。これら
各種製剤は、常法に従って目的に応じて主薬に賦形剤、
結合剤、崩壊剤、滑沢剤、矯味剤、安定化剤などの医薬
の製剤技術分野において通常使用しうる既知の補助剤を
用いて製剤化することができる。When the composition for improving learning ability of the present invention is used as a medicine, the dosage form may be any dosage form as long as oral or parenteral administration is conveniently carried out, for example injection. Liquid, infusion, powder, granule, tablet, capsule, enteric solution, troche, internal solution, suspension, emulsion, syrup, external solution, poultice, nasal drop, ear drop, eye drop, inhalation Agents, ointments, lotions, suppositories, etc. can be mentioned, and these can be used alone or in combination depending on the symptoms. These various preparations are based on the conventional method, depending on the purpose, the main ingredient is an excipient,
It is possible to formulate using known auxiliary agents which can be usually used in the technical field of pharmaceutical preparation such as binders, disintegrants, lubricants, corrigents and stabilizers.
【0019】本発明の学習能力向上剤の投与量は投与経
路、剤形、症状、年齢、体重などによって異なるが、通
常は成人に対し、経口投与の場合、本発明のイミダゾー
ル化合物の総量として50mg〜5g/日、好ましくは1
00mg〜2g/日、より好ましくは50mg〜2g/日、
さらに好ましくは50mg〜500mg/日である。またア
ンセリン及び/又はカルノシンとして50mg〜5g/
日、好ましくは100mg〜2g/日、より好ましくは5
0mg〜2g/日、さらに好ましくは50mg〜500mg/
日であり、π−メチルヒスチジン及び/又はτ−メチル
ヒスチジンとして75mg〜7.5g/日、好ましくは1
50mg〜3g/日、より好ましくは75mg〜3g/日、
さらに好ましくは75mg〜750mg/日である。The dose of the learning ability-improving agent of the present invention varies depending on the administration route, dosage form, symptom, age, body weight and the like. Normally, when administered orally to an adult, the total amount of the imidazole compound of the present invention is 50 mg. ~ 5 g / day, preferably 1
00 mg to 2 g / day, more preferably 50 mg to 2 g / day,
More preferably, it is 50 mg to 500 mg / day. Further, as anserine and / or carnosine, 50 mg to 5 g /
Day, preferably 100 mg to 2 g / day, more preferably 5
0 mg to 2 g / day, more preferably 50 mg to 500 mg /
Day, and 75 mg to 7.5 g / day as π-methylhistidine and / or τ-methylhistidine, preferably 1
50 mg to 3 g / day, more preferably 75 mg to 3 g / day,
More preferably, it is 75 mg to 750 mg / day.
【0020】非経口投与の場合、本発明のイミダゾール
化合物の総量として5mg〜500mg/日、好ましくは1
0mg〜200mg/日、より好ましくは5mg〜200mg/
日、さらに好ましくは5mg〜50mg/日である。またア
ンセリン及び/又はカルノシンとして5mg〜500mg/
日、好ましくは10mg〜200mg/日、より好ましくは
5mg〜200mg/日、さらに好ましくは5mg〜50mg/
日であり、π−メチルヒスチジン及び/又はτ−メチル
ヒスチジンとして7.5mg〜750mg/日、好ましくは
15mg〜300mg/日、より好ましくは7.5mg〜30
0mg/日、さらに好ましくは7.5mg〜75mg/日であ
る。For parenteral administration, the total amount of the imidazole compound of the present invention is 5 mg to 500 mg / day, preferably 1
0 mg to 200 mg / day, more preferably 5 mg to 200 mg /
Day, more preferably 5 mg to 50 mg / day. Also, as anserine and / or carnosine, 5 mg to 500 mg /
Day, preferably 10 mg to 200 mg / day, more preferably 5 mg to 200 mg / day, even more preferably 5 mg to 50 mg / day
It is a day, and is 7.5 mg to 750 mg / day, preferably 15 mg to 300 mg / day, more preferably 7.5 mg to 30 as π-methylhistidine and / or τ-methylhistidine.
It is 0 mg / day, more preferably 7.5 mg to 75 mg / day.
【0021】本発明の学習能力向上組成物を機能性食品
として用いる場合には、形態としては前述の医薬製剤の
形態でもよいが、アンセリン、カルノシン、バレニン、
π−メチルヒスチジンもしくはτ−メチルヒスチジン又
はこれらを主成分とする抽出物を単独で又は組み合わせ
て、蛋白質(蛋白質源としてはアミノ酸バランスのとれ
た栄養価の高い乳蛋白質、大豆蛋白質、卵白のオリゴペ
プチド、大豆加水分解物等の他、アミノ酸単体の混合物
も使用される)、糖類、脂肪、微量元素、ビタミン類、
乳化剤、香料等とともに配合し、自然流動食、半消化態
栄養食および成分栄養食やドリンク剤等の加工形態とす
ることもできる。When the composition for improving learning ability of the present invention is used as a functional food, it may be in the form of the above-mentioned pharmaceutical preparation, but it may be anserine, carnosine, varenin,
π-Methylhistidine or τ-methylhistidine or an extract containing these as the main components, alone or in combination, is used as a protein (as a protein source, a highly nutritious milk protein with a balanced amino acid, soybean protein, oligopeptide of egg white). , Other than soybean hydrolyzate, a mixture of simple amino acids is also used), sugars, fats, trace elements, vitamins,
It is also possible to mix it with an emulsifier, a flavor, etc. to obtain a processed form such as a natural liquid food, a semi-digestive nutrition food, a component nutrition food or a drink.
【0022】また本発明の機能性食品は、所要量の本発
明のアンセリン、カルノシン、バレニン、π−メチルヒ
スチジン、τ−メチルヒスチジン又はこれらを主成分と
する抽出物を飲食品原料に加えて、一般の製造法により
加工製造することもできる。その配合量は剤形、食品の
形態性状により異なるが、一般には0.001〜50%
が好ましいが特に限定されるものではない。Further, the functional food of the present invention comprises a required amount of anserine, carnosine, varenin, π-methylhistidine, τ-methylhistidine or an extract containing these as a main component in a food or drink raw material, It can also be processed and manufactured by a general manufacturing method. The blending amount varies depending on the dosage form and the morphological characteristics of the food, but generally 0.001 to 50%
Is preferred but not particularly limited.
【0023】食品の形態としては、固形あるいは液状の
食品ないしは嗜好品、例えばパン、麺類、ごはん、菓子
類(ビスケット、クッキー、ケーキ、キャンデー、チョ
コレート、チューインガム、和菓子)、豆腐およびその
加工品などの農産食品、清酒、薬用酒などの発酵食品、
みりん、食酢、醤油、味噌、ドレッシング、ヨーグル
ト、ハム、ベーコン、ソーセージ、マヨネーズなどの蓄
農食品、かまぼこ、揚げ天、はんぺんなどの水産食品、
果汁飲料、清涼飲料、スポーツ飲料、アルコール飲料、
茶などの飲料等が挙げられる。The form of the food includes solid or liquid food or a favorite product such as bread, noodles, rice, confectionery (biscuits, cookies, cakes, candy, chocolate, chewing gum, Japanese confectionery), tofu and processed products thereof. Agricultural foods, sake, fermented foods such as medicinal liquor,
Agricultural foods such as mirin, vinegar, soy sauce, miso, dressing, yogurt, ham, bacon, sausage, mayonnaise, fish products such as kamaboko, fried tempura, and hanpen,
Fruit juice, soft drink, sports drink, alcoholic drink,
Examples thereof include beverages such as tea.
【0024】また本発明の機能性食品は、アンセリン、
カルノシン、バレニン、π−メチルヒスチジン、及びτ
−メチルヒスチジンの群から選ばれた1種以上のイミダ
ゾール化合物を含有している天然物から、アンセリン、
カルノシン、バレニン、π−メチルヒスチジン、及びτ
−メチルヒスチジンの群から選ばれた1種以上のイミダ
ゾール化合物を抽出することにより製造することができ
る。このようにして得られた本発明のイミダゾール化合
物を主成分とする抽出物、例えば鶏肉等から常法に従っ
て抽出された抽出物を、前述の医薬製剤の形態で、例え
ばドリンク剤やカプセル剤、顆粒剤として、使用するこ
とができる。The functional food of the present invention is anserine,
Carnosine, Valenin, π-Methylhistidine, and τ
-From natural products containing one or more imidazole compounds selected from the group of methylhistidine, anserine,
Carnosine, Valenin, π-Methylhistidine, and τ
-It can be produced by extracting one or more imidazole compounds selected from the group of methylhistidine. The extract containing the imidazole compound of the present invention thus obtained as a main component, for example, an extract extracted according to a conventional method from chicken etc., in the form of the aforementioned pharmaceutical preparation, for example, a drink, a capsule or a granule. It can be used as an agent.
【0025】また本発明のイミダゾール化合物は、ビタ
ミン剤やホルモン剤その他の栄養剤、また微量元素や鉄
化合物と併用することができる。また本発明の機能性食
品は、学習能力を向上させる、あるいは精神疲労を予防
し、又は精神疲労からの回復を促進させる、意識を高揚
させる、集中力を増強させること等を目的として、本発
明のイミダゾール化合物の総量として1日あたり50mg
以上、好ましくは100mg以上、より好ましくは50mg
〜5g、より好ましくは100mg〜2g、より好ましく
は50mg〜2g、さらに好ましくは50mg〜500mgの
範囲で経口摂取されることが望ましい。The imidazole compound of the present invention can be used in combination with vitamins, hormones and other nutritional supplements, as well as trace elements and iron compounds. Further, the functional food of the present invention, for the purpose of improving learning ability, or preventing mental fatigue, or promoting recovery from mental fatigue, elevating consciousness, enhancing concentration, etc. 50mg per day as total amount of imidazole compound
Or more, preferably 100 mg or more, more preferably 50 mg
˜5 g, more preferably 100 mg to 2 g, more preferably 50 mg to 2 g, and even more preferably 50 mg to 500 mg.
【0026】またアンセリン及び/又はカルノシンとし
て1日あたり50mg以上、好ましくは100mg以上、よ
り好ましくは50mg〜5g、より好ましくは100mg〜
2g、より好ましくは50mg〜2g、さらに好ましくは
50mg〜500mgの範囲で経口摂取されることが望まし
い。またπ−メチルヒスチジン及び/又はτ−メチルヒ
スチジンとして1日あたり75mg以上、好ましくは15
0mg以上、より好ましくは75mg〜7.5g、より好ま
しくは150mg〜3g、より好ましくは75mg〜3g、
さらに好ましくは75mg〜750mgの範囲で経口摂取さ
れることが望ましい。Further, as anserine and / or carnosine, the daily dose is 50 mg or more, preferably 100 mg or more, more preferably 50 mg to 5 g, and further preferably 100 mg to
2 g, more preferably 50 mg to 2 g, and even more preferably 50 mg to 500 mg is orally ingested. Further, as π-methylhistidine and / or τ-methylhistidine, 75 mg or more per day, preferably 15
0 mg or more, more preferably 75 mg to 7.5 g, more preferably 150 mg to 3 g, more preferably 75 mg to 3 g,
More preferably, it is desirable to be ingested orally in the range of 75 mg to 750 mg.
【0027】また本発明の機能性食品は、健康な人への
利用にとどまらず、痴呆症の老人や、医師の指示に基づ
く栄養士の管理下にある患者等に与えることもできる。
本発明のアンセリン、カルノシン、バレニン、π−メチ
ルヒスチジン、τ−メチルヒスチジンは元来生体内に存
在する物質であるため、低毒性で安全性も高いことか
ら、学習能力向上組成物としての意義も大きい。The functional food of the present invention can be applied not only to healthy people but also to elderly people with dementia, patients under the control of a dietitian based on the instructions of a doctor, and the like.
Since anserine, carnosine, valenin, π-methylhistidine, τ-methylhistidine of the present invention are substances originally existing in the living body, they have low toxicity and high safety, and therefore have great significance as a learning ability improving composition. .
【0028】本発明のアンセリン、カルノシン、バレニ
ン、π−メチルヒスチジン、及びτ−メチルヒスチジン
を実質上含有しない飲食物に、アンセリン、カルノシ
ン、バレニン、π−メチルヒスチジン、及びτ−メチル
ヒスチジンの群から選ばれた1種以上のイミダゾール化
合物、又はこれを主成分とする抽出物を添加してなる新
規な飲食品において、アンセリン、カルノシン、バレニ
ン、π−メチルヒスチジン、τ−メチルヒスチジンを実
質上含有しない飲食物としては、例えば牛肉、豚肉、鶏
肉、魚肉、鯨肉、蛇肉等の肉類を原料としない飲食物
や、牛肉、豚肉、鶏肉、魚肉、鯨肉、蛇肉等の肉類のエ
キスを使用していない飲食物が挙げられる。The foods and drinks of the present invention containing substantially no anserine, carnosine, valenin, π-methylhistidine, and τ-methylhistidine, include anserine, carnosine, valenin, π-methylhistidine, and τ-methylhistidine. A novel food or drink obtained by adding one or more selected imidazole compounds or an extract containing the same as a main component does not substantially contain anserine, carnosine, varenin, π-methylhistidine, τ-methylhistidine. As the food and drink, for example, foods and drinks that are not made of meat such as beef, pork, chicken, fish, whale, and snake meat, and meat extracts such as beef, pork, chicken, fish, whale, and snake meat are used. Food and drink that you have not done.
【0029】しかしながら、牛肉、豚肉、鶏肉、魚肉、
鯨肉、蛇肉等の肉類を原料とする飲食物であっても、ア
ンセリン、カルノシン、バレニン、π−メチルヒスチジ
ン、τ−メチルヒスチジンの製品含量が極微量であるた
め、1日摂取量あたりのアンセリン、カルノシン、バレ
ニン、π−メチルヒスチジン、τ−メチルヒスチジンの
総合量が50mg以下のもの、好ましくは100mg以下の
もの、より好ましくは400mg以下のもの、さらに好ま
しくは500mg以下のもの、あるいは1日摂取量あたり
のアンセリン及び/又はカルノシンの含量が50mg以下
のもの、好ましくは100mg以下のもの、より好ましく
は400mg以下のもの、さらに好ましくは500mg以下
のものは、本発明のアンセリン、カルノシン、バレニ
ン、π−メチルヒスチジン、τ−メチルヒスチジンを実
質上含有しない飲食物に含まれる。However, beef, pork, chicken, fish,
Even for foods and drinks made from meat such as whale meat and snake meat, since the product content of anserine, carnosine, varenin, π-methylhistidine, τ-methylhistidine is extremely small, per daily intake Anserine, carnosine, valenin, π-methylhistidine, τ-methylhistidine in a total amount of 50 mg or less, preferably 100 mg or less, more preferably 400 mg or less, further preferably 500 mg or less, or 1 day Those having an anserine and / or carnosine content per ingestion of 50 mg or less, preferably 100 mg or less, more preferably 400 mg or less, still more preferably 500 mg or less are the anserine, carnosine, and varenin of the present invention. π-Methylhistidine, τ-Methylhistidine included in foods and drinks that do not substantially contain You.
【0030】また本発明の新規な飲食品の範疇には、ア
ンセリン、カルノシン、バレニン、π−メチルヒスチジ
ン、及びτ−メチルヒスチジンを実質上含有しない飲食
物以上に、アンセリン、カルノシン、バレニン、π−メ
チルヒスチジン、及びτ−メチルヒスチジンの群から選
ばれた1種以上のイミダゾール化合物を含有するように
抽出された抽出物も含まれる。Further, in the category of the novel food and drink of the present invention, anserine, carnosine, valenin, π-, and more than foods and drinks containing substantially no anserine, carnosine, varenin, π-methylhistidine, and τ-methylhistidine. Also included are extracts extracted to contain methylhistidine and one or more imidazole compounds selected from the group of τ-methylhistidine.
【0031】本発明の新規な飲食品は、所要量の本発明
のアンセリン、カルノシン、バレニン、π−メチルヒス
チジン、τ−メチルヒスチジン又はこれらを主成分とす
る抽出物を飲食品原料に加えて、一般の製造法により加
工製造することができる。その配合量は剤形、食品の形
態性状により異なるが、一般には0.001〜50%が
好ましいが特に限定されるものではない。飲食品の形態
としては前述の医薬製剤の形態でも、また前述の機能性
食品の形態であってもよい。The novel food and drink of the present invention comprises the required amount of anserine, carnosine, valenine, π-methylhistidine, τ-methylhistidine or an extract containing these as the main ingredients, and It can be processed and manufactured by a general manufacturing method. The blending amount varies depending on the dosage form and the morphological characteristics of the food, but is generally preferably 0.001 to 50%, but is not particularly limited. The form of the food or drink may be the form of the above-mentioned pharmaceutical preparation or the form of the above-mentioned functional food.
【0032】また本発明の新規な飲食品は、アンセリ
ン、カルノシン、バレニン、π−メチルヒスチジン、及
びτ−メチルヒスチジンの群から選ばれた1種以上のイ
ミダゾール化合物を含有している天然物から、常法に従
って1日摂取量あたりのアンセリン、カルノシン、バレ
ニン、π−メチルヒスチジン、τ−メチルヒスチジンの
総量が50mgより多く、好ましくは100mgより多く、
より好ましくは400mgより多く、さらに好ましくは5
00mgより多くなるように、アンセリン、カルノシン、
バレニン、π−メチルヒスチジン、及びτ−メチルヒス
チジンの群から選ばれた1種以上のイミダゾール化合物
を含有するように抽出することにより製造することがで
きる。The novel food or drink of the present invention is a natural product containing at least one imidazole compound selected from the group consisting of anserine, carnosine, valenin, π-methylhistidine, and τ-methylhistidine. According to the usual method, the total amount of anserine, carnosine, valenin, π-methylhistidine, τ-methylhistidine per daily intake is more than 50 mg, preferably more than 100 mg,
More preferably more than 400 mg, even more preferably 5
Anserine, carnosine, so that it is more than 00mg
It can be produced by extraction so as to contain one or more imidazole compounds selected from the group of valenin, π-methylhistidine, and τ-methylhistidine.
【0033】また本発明の飲食品は、学習能力を向上さ
せる、あるいは精神疲労を予防し、又は精神疲労からの
回復を促進させる、意識を高揚させる、集中力を増強さ
せること等を目的として、前述の機能性食品の摂取量に
ならって経口摂取することができる。Further, the food or drink of the present invention has the purpose of improving learning ability, preventing mental fatigue, promoting recovery from mental fatigue, elevating consciousness, enhancing concentration, etc. It can be taken orally according to the above-mentioned intake of functional food.
【0034】[0034]
【実施例】以下実施例により、本発明をより具体的に説
明するが、本発明はこれらに限定されるものではない。実施例1. 健康な男子大学生16名に対して、1本あた
りアンセリンを150mgおよびカルノシンを50mg含有
する鶏肉エキス(BRAND′S TRADITION
AL ESSENCE OF CHICKEN;Cerebo
s Pacific Ltd .)を1日1回2本、1週間飲用した場
合と、これらのイミダゾール化合物を含有しないゼラチ
ン水溶液(プラセボ)を1日1回2本、1週間飲用した
場合とで、計算力試験および短期記憶力試験を実施し、
自覚される精神的疲労感、活力感等の比較を行なった。
また、計算力試験および短期記憶力試験の能率と正確さ
に与える影響を比較した。The present invention will be described in more detail with reference to the following examples, but the present invention is not limited thereto. Embodiment 1 FIG. For 16 healthy male college students, chicken extract containing 150 mg of anserine and 50 mg of carnosine (BRAND'S TRADITION)
AL ESSENCE OF CHICKEN; Cerebo
s Pacific Ltd. ) Was taken twice a day for 1 week and a gelatin aqueous solution (placebo) not containing these imidazole compounds was taken twice a day for 1 week, and the calculation test and short-term memory ability were evaluated. Conduct a test,
We compared the feeling of mental fatigue and vitality.
We also compared the effects of computational and short-term memory tests on efficiency and accuracy.
【0035】計算力試験には、1枚40問の2桁あるい
は3桁の加算、減算課題からなる計算課題40枚(計
1,600問)を用いた。1枚に1分間の制限時間が設
けられており40分間の作業課題とした。短期記憶力試
験には、数列記憶課題を用いた。9桁の数列を5秒間呈
示し、それを被験者に記憶させ、直後に制限時間5秒間
で再生、記述させた。数列記憶課題は1問9点満点と
し、20問連続で実施した。自覚される精神的疲労感、
活力感等は「気分状態尺度Profile of Mood State(POM
S) 」を用いて評価した。この評価法は気分を表わす6
5項目のことばに対して5段階尺度で評定する質問紙
で、「緊張」「抑圧」「高揚」「活力」「疲労」「動
揺」及び「優しさ」の7つの要因ごとに解析ができる特
徴をもっている。For the calculation ability test, 40 pieces of calculation tasks consisting of two-digit or three-digit addition and subtraction tasks of 40 questions (1,600 questions in total) were used. There was a time limit of 1 minute for each sheet, and the task was 40 minutes. A sequence memory task was used for the short-term memory test. A 9-digit sequence was presented for 5 seconds, the subject was made to remember it, and immediately after that, it was reproduced and described for a limited time of 5 seconds. The number sequence task was a total of 1 question and 9 points. Feeling mental fatigue,
For the vitality etc., refer to “Mood State Scale Profile of Mood State (POM
S) ”. This evaluation method represents mood 6
It is a questionnaire that evaluates the words of 5 items on a scale of 5 levels, and can analyze for each of 7 factors of "tension", "repression", "uplifting", "vigor", "fatigue", "upset" and "kindness". I have
【0036】図1に計算課題直後の気分状態スコアーの
変化を示す。プラセボ飲用時には、40分間の計算とい
う過度の精神活動によって疲労感の増加、活力の低下、
高揚感の低下が認められたが、これに対してアンセリ
ン、カルノシン含有物の飲用時には疲労感増加の有意な
抑制、活力低下の抑制、高揚感の有意な増加が認められ
た。これはアンセリン、カルノシン含有物が過度の精神
活動による疲労感を有効に軽減し、集中力を増強する抗
精神疲労効果を示したことを意味している。FIG. 1 shows changes in the mood state score immediately after the calculation task. When taking a placebo, excessive mental activity of 40 minutes of calculation increased fatigue, decreased vitality,
Although a reduction in uplifting feeling was observed, a significant increase in fatigue feeling, a decrease in vitality, and a significant increase in uplifting feeling were observed when the substance containing anserine and carnosine was taken. This means that the substances containing anserine and carnosine effectively reduced the feeling of fatigue caused by excessive mental activity, and exhibited an antipsychotic fatigue effect that enhances concentration.
【0037】図2に数列記憶課題直後の気分状態スコア
ーの変化を示す。プラセボ飲用時には、連続20問の数
列記憶という過度の精神活動によって疲労感の増加およ
び活力の低下が認められたが、これに対してアンセリ
ン、カルノシン含有物の飲用時には疲労感増加の抑制、
活力低下の有意な抑制、高揚感の増加、緊張感の有意な
増加が認められた。これはアンセリン、カルノシン含有
物が過度の精神活動による疲労感を有効に軽減し、集中
力を増強する抗精神疲労効果を示したことを意味してい
る。FIG. 2 shows changes in the mood state score immediately after the sequence memory task. An increase in fatigue and a decrease in vitality were observed due to excessive mental activity of sequence memory of 20 consecutive questions when taking placebo, whereas an increase in fatigue was suppressed when taking anserine and carnosine-containing substances,
Significant suppression of decline in vitality, increase in uplifting feeling, and significant increase in tension were observed. This means that the substances containing anserine and carnosine effectively reduced the feeling of fatigue caused by excessive mental activity, and exhibited an antipsychotic fatigue effect that enhances concentration.
【0038】図3に計算課題の回答数を示す。アンセリ
ン、カルノシン含有物の飲用時はブラセボ飲用時と比較
して回答数が増加したが、これはアンセリン、カルノシ
ン含有物が集中力を増強し学習能力における作業効率を
向上させたことを示している。図4に計算課題の正答数
を示す。アンセリン、カルノシン含有物の飲用時は、ブ
ラセボ飲用時と比較して正答数が増加したが、これはア
ンセリン、カルノシン含有物が集中力を増強し学習能力
における作業の正確さを向上させたことを示している。FIG. 3 shows the number of answers to the calculation task. The number of responses increased when the anserine / carnosine-containing product was taken compared to when the placebo was taken, which indicates that the anserine / carnosine-containing product enhanced concentration and improved work efficiency in learning ability. . Figure 4 shows the number of correct answers for the calculation task. The number of correct answers increased when the anserine / carnosine-containing product was taken compared to when the placebo was taken, which indicates that the anserine / carnosine-containing product increased the concentration and improved the accuracy of work in learning ability. Shows.
【0039】図5に計算課題の誤答率を示す。アンセリ
ン、カルノシン含有物の飲用時は、ブラセボ飲用時と比
較して誤答率が低下したが、これはアンセリン、カルノ
シン含有物が集中力を増強し学習能力における作業の正
確さを向上させたことを示している。図6に数列記憶課
題前半10問の平均得点を示す。アンセリン、カルノシ
ン含有物の飲用時は、ブラセボ飲用時と比較して平均得
点が増加したが、これはアンセリン、カルノシン含有物
が集中力を増強し学習能力における作業の正確さを向上
させたことを示している。FIG. 5 shows the incorrect answer rate of the calculation task. When an anserine / carnosine-containing substance was taken, the error rate was lower than when it was administered a placebo, but this was due to the fact that the anserine / carnosine-containing substance increased concentration and improved the accuracy of work in learning ability. Is shown. FIG. 6 shows the average score of the first 10 questions of the sequence memory task. The average score was higher when the anserine / carnosine-containing product was taken compared to when the placebo was taken, which means that the anserine / carnosine-containing product increased the concentration and improved the accuracy of work in learning ability. Shows.
【0040】実施例2.マグロ缶詰製造時に排出する煮
汁の濃縮液を分子量10000で分別する限外濾過膜で
処理し、低分子画分の清澄液を得た。希塩酸を用いて清
澄液のpHを2.2に調製した後、この液をベックマン
社、MM81タイプイオン交換樹脂を充填したカラムに
流し、アンセリン、カルノシンを吸着させた。その後カ
ラムを57℃に保温した状態で、0.4Nクエン酸ナト
リウム液を流し、アンセリン及びカルノシンを含有する
画分を得た。これを凍結乾燥し乾燥物を得た。この乾燥
物についてアミノ酸分析計によりアンセリンあるいはカ
ルノシン、π−メチルヒスチジンの含量を測定したとこ
ろそれぞれ41%、12%、5%であった。 Embodiment 2 FIG . The concentrated liquid of the broth discharged during the production of canned tuna was treated with an ultrafiltration membrane to separate it with a molecular weight of 10,000 to obtain a clarified liquid of a low molecular weight fraction. After the pH of the clarified liquid was adjusted to 2.2 with dilute hydrochloric acid, this liquid was passed through a column packed with MM81 type ion exchange resin manufactured by Beckman Co. to adsorb anserine and carnosine. Then, with the column kept warm at 57 ° C., 0.4N sodium citrate solution was flown to obtain a fraction containing anserine and carnosine. This was freeze-dried to obtain a dried product. The contents of anserine, carnosine, and π-methylhistidine in the dried product were measured by an amino acid analyzer and were 41%, 12% and 5%, respectively.
【0041】実施例3.乳糖50部、蔗糖39.8部、
トラガントガム5部、ペパーミント0.2部を混合し、
これに実施例2で得られた乾燥物をイミダゾール化合物
換算で5部を蒸留水3.5部に溶解した溶液を加え、よ
く練り合わせた。次に澱粉を散布したガラス板上に上記
の練合物をめん棒で伸展して厚さ約5mmのシート状とし
て後、型で打ち抜き、乾燥してトローチとした。 Embodiment 3 FIG . Lactose 50 parts, sucrose 39.8 parts,
Mix 5 parts of tragacanth gum and 0.2 parts of peppermint,
A solution prepared by dissolving 5 parts of the dried product obtained in Example 2 in 3.5 parts of distilled water in terms of imidazole compound was added and kneaded well. Then, the above kneaded product was spread on a glass plate on which starch was sprayed with a rolling pin to form a sheet having a thickness of about 5 mm, which was punched out with a mold and dried to obtain a troche.
【0042】実施例4.小麦粉100部にカルノシン2
部、蔗糖4部、食塩1.1部、脱脂粉乳2部、イースト
3部、イーストフード0.8部、水67.2部を加えて
捏ねた後、更に油脂5部を加えよく捏ねた。28℃で9
0分間の第一次発酵を行った。その後、パンチングを行
い、28℃、20分間の第二次発酵を行った後、成形型
に詰めて190℃で30分焼き製造した。焼き上がり後
のパンの物性についてカルノシンを加えずに製造したパ
ンと比較した結果、風味、食感ともに差は認められなか
った。 Embodiment 4 FIG . Carnosine 2 on 100 parts flour
Parts, sucrose 4 parts, salt 1.1 parts, skim milk powder 2 parts, yeast 3 parts, yeast food 0.8 parts, and water 67.2 parts were added and kneaded, and then 5 parts of oil and fat were further added and kneaded well. 9 at 28 ° C
A 0-minute primary fermentation was performed. After that, punching was performed, and second fermentation was performed at 28 ° C. for 20 minutes, and then the mixture was packed in a mold and baked at 190 ° C. for 30 minutes to manufacture. The physical properties of the baked bread were compared with those of the bread produced without adding carnosine, and no difference was found in flavor and texture.
【0043】実施例5.豚肉80部に、BRAND′S
TRADITIONAL ESSENCEOF CH
ICKEN(Cerebos Pacific Ltd .)をアンセリンと
カルノシンの合計量換算で2部、亜硝酸ナトリウム0.
02部、食塩2部、ピロリン酸ナトリウム0.3部、ア
スコルビン酸ナトリウム0.006部、蔗糖1部を加
え、10℃で72時間塩漬の後、調味料、香辛料を加え
カッティングし、練り肉を調製した。この練り肉をケー
シングに詰めた後、常法に従いソーセージを製造した。
このソーセージを官能検査した結果、BRAND′S
TRADITIONALESSENCE OF CHI
CKENを加えずに製造したソーセージと比較して、色
調、風味、食感ともに差は認められなかった。 Example 5. BRAND'S on 80 parts of pork
TRADITIONAL ESSENCE OF CH
2 parts of ICKEN (Cerebos Pacific Ltd.) in terms of total amount of anserine and carnosine, sodium nitrite 0.
Add 02 parts, 2 parts salt, 0.3 parts sodium pyrophosphate, 0.006 parts sodium ascorbate, 1 part sucrose and salt for 72 hours at 10 ° C, then add seasonings and spices and cut, Was prepared. After filling this kneaded meat in a casing, a sausage was produced according to a conventional method.
As a result of sensory inspection of this sausage, BRAND'S
TRADITIONALESSENCE OF CHI
No difference in color tone, flavor, or texture was observed as compared to sausage produced without the addition of CKEN.
【0044】実施例6.合成したアンセリンを用いて下
記の処方で常法により顆粒剤を製造した。 アンセリン 20部 乳糖 34部 とうもろこし澱粉 45部 ヒドロキシプロピルメチルセルロース 1部 Example 6. Using the synthesized anserine, granules were manufactured by the usual method according to the following formulation. Anserine 20 parts Lactose 34 parts Corn starch 45 parts Hydroxypropyl methylcellulose 1 part
【0045】実施例7.ビタミンC20g、硫酸第一鉄
10g、グラニュー糖40g、コーンスターチと乳糖の
等量混合物30gに、実施例2で得た抽出物を50g加
えて混合した。混合物を100等分して袋に詰め、1袋
1.5gの学習能力の向上作用を有するスティック状機
能性食品100袋を製造した。 Example 7. To 20 g of vitamin C, 10 g of ferrous sulfate, 40 g of granulated sugar, and 30 g of an equal mixture of corn starch and lactose, 50 g of the extract obtained in Example 2 was added and mixed. The mixture was divided into 100 equal parts and packed in a bag to produce 100 bags of a functional stick-shaped food having an effect of improving learning ability of 1.5 g per bag.
【図1】図1は、実施例1において、計算課題を課した
直後の気分状態スコアーに対するアンセリン及びカルノ
シンの効果を示す。1 shows the effect of anserine and carnosine on mood state scores immediately after imposing a computational task in Example 1. FIG.
【図2】図2は、実施例1における、数列記憶課題を課
した直後の気分状態スコアーに対するアンセリン及びカ
ルノシンの効果を示す。FIG. 2 shows the effect of anserine and carnosine on mood state scores immediately after imposing a sequence memory task in Example 1.
【図3】図3は、実施例1における、計算課題の回答数
に対するアンセリン及びカルノシンの効果を示す。FIG. 3 shows the effect of anserine and carnosine on the number of answers to a calculation task in Example 1.
【図4】図4は、実施例1における、計算課題の正答数
に対するアンセリン及びカルノシンの効果を示す。FIG. 4 shows the effect of anserine and carnosine on the number of correct answers in the calculation task in Example 1.
【図5】図5は、実施例1における、計算課題の誤答率
に対するアンセリン及びカルノシンの効果を示す。FIG. 5 shows the effect of anserine and carnosine on the incorrect answer rate of the calculation task in Example 1.
【図6】図6は、実施例1における、数列記憶課題前半
10問の平均得点に対するアンセリン及びカルノシンの
効果を示す。FIG. 6 shows the effect of anserine and carnosine on the average score of 10 questions in the first half of the sequence memory task in Example 1.
Claims (11)
−メチルヒスチジン及びτ−メチルヒスチジンの群から
選ばれた1種以上のイミダゾール化合物を含有してなる
学習能力向上組成物。1. Anserine, carnosine, valenin, π
-A learning ability improving composition comprising one or more imidazole compounds selected from the group of -methylhistidine and τ-methylhistidine.
向上組成物。2. The learning ability improving composition according to claim 1, which is a medicine.
能力向上組成物。3. The learning ability improving composition according to claim 1, which is a functional food.
のイミダゾール化合物を摂取できるような形態の機能性
食品である、請求項3に記載の学習能力向上組成物。4. The learning ability improving composition according to claim 3, wherein the functional food is a functional food in a form in which 50 mg to 5 g / day of an imidazole compound can be ingested.
及び/又はカルノシンである請求項1〜4のいずれか1
項に記載の学習能力向上組成物。5. The imidazole compound is anserine and / or carnosine, according to claim 1.
A composition for improving learning ability according to the item.
−メチルヒスチジン及びτ−メチルヒスチジンを実質上
含有しない飲食物に、アンセリン、カルノシン、バレニ
ン、π−メチルヒスチジン及びτ−メチルヒスチジンの
群から選ばれた1種以上のイミダゾール化合物、又はこ
れを主成分とする抽出物を添加してなる新規な飲食品。6. Anserine, carnosine, valenin, π
-Methylhistidine and τ-methylhistidine substantially in food and drink, anserine, carnosine, valenin, one or more imidazole compound selected from the group of π-methylhistidine and τ-methylhistidine, or the main component thereof A new food or drink product to which the extract described above is added.
る、請求項6に記載の飲食品。7. The food or drink according to claim 6, which is a food or drink having an effect of improving learning ability.
を摂取できるような形態であることを特徴とする請求項
6又は7記載の飲食品。8. The food or drink according to claim 6 or 7, which is in a form in which 50 mg to 5 g / day of an imidazole compound can be ingested.
−メチルヒスチジン及びτ−メチルヒスチジンを実質上
含有しない飲食物に、アンセリン、カルノシン、バレニ
ン、π−メチルヒスチジン及びτ−メチルヒスチジンの
群から選ばれた1種以上のイミダゾール化合物、又はこ
れを主成分とする抽出物を添加することを特徴とする新
規な飲食品の製造方法。9. Anserine, carnosine, valenin, π
-Methylhistidine and τ-methylhistidine substantially in food and drink, anserine, carnosine, valenin, one or more imidazole compound selected from the group of π-methylhistidine and τ-methylhistidine, or the main component thereof A novel method for producing a food or drink, comprising adding the extract
する飲食品である、請求項9に記載の飲食品の製造方
法。10. The method for producing a food or drink according to claim 9, wherein the food or drink is a food or drink having an effect of improving learning ability.
ダゾール化合物を摂取できるような形態の飲食品であ
る、請求項9又は10に記載の方法。11. The method according to claim 9, wherein the food or drink is a food or drink in a form capable of ingesting 50 mg to 5 g / day of an imidazole compound.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7168749A JPH0920661A (en) | 1995-07-04 | 1995-07-04 | Learning ability-improving composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7168749A JPH0920661A (en) | 1995-07-04 | 1995-07-04 | Learning ability-improving composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH0920661A true JPH0920661A (en) | 1997-01-21 |
Family
ID=15873719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7168749A Pending JPH0920661A (en) | 1995-07-04 | 1995-07-04 | Learning ability-improving composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0920661A (en) |
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11322617A (en) * | 1998-05-07 | 1999-11-24 | Tokiwa Yakuhin Kogyo Kk | Pharmaceutical composition for preventing or treating gastric ulcer comprising chicken or oyster extract |
| WO2003013514A1 (en) * | 2001-08-08 | 2003-02-20 | Carn-Aware Llc | Improving neurological functions |
| JP2003102435A (en) * | 2001-09-28 | 2003-04-08 | New Food Creation Gijutsu Kenkyu Kumiai | High-grade chicken extract-containing functional food and method for producing the same |
| JP2003102436A (en) * | 2001-09-28 | 2003-04-08 | New Food Creation Gijutsu Kenkyu Kumiai | Processed chicken extract membrane and its contents |
| JP2003192611A (en) * | 2001-12-27 | 2003-07-09 | Nonogawa Shoji Kk | Preventive agent or therapeutic agent of osteoporosis |
| JP2003192610A (en) * | 2001-12-27 | 2003-07-09 | Nonogawa Shoji Kk | Preventive agent or therapeutic agent of osteoporosis |
| US6855727B2 (en) | 2000-12-04 | 2005-02-15 | Yaizu Suisankagaku Industry Co., Ltd. | Muscular fatigue-controlling composition and method for providing muscular fatigue-controlling effect |
| WO2005087022A1 (en) * | 2004-03-12 | 2005-09-22 | Ajinomoto Co., Inc. | Food composition having antistress effect |
| WO2007029834A1 (en) * | 2005-09-09 | 2007-03-15 | Ajinomoto Co., Inc. | Food composition |
| WO2007086354A1 (en) | 2006-01-24 | 2007-08-02 | Nippon Zoki Pharmaceutical Co., Ltd. | Novel histidine derivative |
| WO2007116987A1 (en) * | 2006-03-31 | 2007-10-18 | Nippon Meat Packers, Inc. | Functional food and drug having learning function-improving effect and antidepressant effect |
| JP2007314467A (en) * | 2006-05-25 | 2007-12-06 | Takahashi Gakuen | Food and drink for prevention or treatment of cerebrovascular dementia, its package or container and agent for prevention or treatment of cerebrovascular dementia |
| WO2009014097A1 (en) | 2007-07-23 | 2009-01-29 | Nippon Zoki Pharmaceutical Co., Ltd. | Novel histidine derivative |
| EP1550377A4 (en) * | 2002-10-11 | 2012-08-15 | Ajinomoto Kk | Food compositions for recovery from fatigue |
| US8354438B2 (en) | 2001-08-08 | 2013-01-15 | Michael Chez | Neurological functions |
| WO2015053336A1 (en) * | 2013-10-09 | 2015-04-16 | 味の素株式会社 | Anti-fatigue composition |
| JP2016102068A (en) * | 2014-11-27 | 2016-06-02 | Shiodaライフサイエンス株式会社 | Medium-to-long term memory impairment preventing and improving agent comprising whale muscle extract |
| JPWO2015053337A1 (en) * | 2013-10-09 | 2017-03-09 | 味の素株式会社 | Food containing histidine and use thereof |
| JP2018083808A (en) * | 2016-11-15 | 2018-05-31 | 日本ハム株式会社 | Exosome regulatory agent containing imidazole dipeptide, and neuronal activation enhancer containing exosome |
| JP2021017402A (en) * | 2019-07-17 | 2021-02-15 | 東海物産株式会社 | Composition for improving mild cognitive impairment, and method for improving mild cognitive impairment using the composition |
| CN113195003A (en) * | 2018-11-30 | 2021-07-30 | 国立大学法人京都大学 | Drug delivery system using solution |
-
1995
- 1995-07-04 JP JP7168749A patent/JPH0920661A/en active Pending
Cited By (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11322617A (en) * | 1998-05-07 | 1999-11-24 | Tokiwa Yakuhin Kogyo Kk | Pharmaceutical composition for preventing or treating gastric ulcer comprising chicken or oyster extract |
| US6855727B2 (en) | 2000-12-04 | 2005-02-15 | Yaizu Suisankagaku Industry Co., Ltd. | Muscular fatigue-controlling composition and method for providing muscular fatigue-controlling effect |
| WO2003013514A1 (en) * | 2001-08-08 | 2003-02-20 | Carn-Aware Llc | Improving neurological functions |
| US8354438B2 (en) | 2001-08-08 | 2013-01-15 | Michael Chez | Neurological functions |
| JP2003102436A (en) * | 2001-09-28 | 2003-04-08 | New Food Creation Gijutsu Kenkyu Kumiai | Processed chicken extract membrane and its contents |
| JP2003102435A (en) * | 2001-09-28 | 2003-04-08 | New Food Creation Gijutsu Kenkyu Kumiai | High-grade chicken extract-containing functional food and method for producing the same |
| JP2003192610A (en) * | 2001-12-27 | 2003-07-09 | Nonogawa Shoji Kk | Preventive agent or therapeutic agent of osteoporosis |
| JP2003192611A (en) * | 2001-12-27 | 2003-07-09 | Nonogawa Shoji Kk | Preventive agent or therapeutic agent of osteoporosis |
| EP1550377A4 (en) * | 2002-10-11 | 2012-08-15 | Ajinomoto Kk | Food compositions for recovery from fatigue |
| WO2005087022A1 (en) * | 2004-03-12 | 2005-09-22 | Ajinomoto Co., Inc. | Food composition having antistress effect |
| JPWO2005087022A1 (en) * | 2004-03-12 | 2008-01-24 | 味の素株式会社 | Food composition having anti-stress effect |
| WO2007029834A1 (en) * | 2005-09-09 | 2007-03-15 | Ajinomoto Co., Inc. | Food composition |
| WO2007086354A1 (en) | 2006-01-24 | 2007-08-02 | Nippon Zoki Pharmaceutical Co., Ltd. | Novel histidine derivative |
| US8236844B2 (en) | 2006-01-24 | 2012-08-07 | Nippon Zoki Pharmaceutical Co., Ltd. | Histidine derivatives |
| JPWO2007116987A1 (en) * | 2006-03-31 | 2009-08-20 | 日本ハム株式会社 | Functional foods and drugs with learning function improvement and anti-anxiety effects |
| WO2007116987A1 (en) * | 2006-03-31 | 2007-10-18 | Nippon Meat Packers, Inc. | Functional food and drug having learning function-improving effect and antidepressant effect |
| JP2007314467A (en) * | 2006-05-25 | 2007-12-06 | Takahashi Gakuen | Food and drink for prevention or treatment of cerebrovascular dementia, its package or container and agent for prevention or treatment of cerebrovascular dementia |
| WO2009014097A1 (en) | 2007-07-23 | 2009-01-29 | Nippon Zoki Pharmaceutical Co., Ltd. | Novel histidine derivative |
| US8324261B2 (en) | 2007-07-23 | 2012-12-04 | Nippon Zoki Pharmaceutical Co., Ltd. | Histidine derivatives |
| JPWO2015053337A1 (en) * | 2013-10-09 | 2017-03-09 | 味の素株式会社 | Food containing histidine and use thereof |
| WO2015053336A1 (en) * | 2013-10-09 | 2015-04-16 | 味の素株式会社 | Anti-fatigue composition |
| EP3066937A4 (en) * | 2013-10-09 | 2017-11-01 | Ajinomoto Co., Inc. | Foodstuff containing histidine and application therefor |
| US10369163B2 (en) | 2013-10-09 | 2019-08-06 | Ajinomoto Co., Inc. | Anti-fatigue composition |
| US10390553B2 (en) | 2013-10-09 | 2019-08-27 | Ajinomoto Co., Inc. | Food containing histidine and use thereof |
| JP2020156524A (en) * | 2013-10-09 | 2020-10-01 | 味の素株式会社 | Foods containing histidine and their uses |
| JP2016102068A (en) * | 2014-11-27 | 2016-06-02 | Shiodaライフサイエンス株式会社 | Medium-to-long term memory impairment preventing and improving agent comprising whale muscle extract |
| JP2018083808A (en) * | 2016-11-15 | 2018-05-31 | 日本ハム株式会社 | Exosome regulatory agent containing imidazole dipeptide, and neuronal activation enhancer containing exosome |
| CN113195003A (en) * | 2018-11-30 | 2021-07-30 | 国立大学法人京都大学 | Drug delivery system using solution |
| JPWO2020111229A1 (en) * | 2018-11-30 | 2021-10-14 | 国立大学法人京都大学 | Drug delivery system using solution |
| JP2021017402A (en) * | 2019-07-17 | 2021-02-15 | 東海物産株式会社 | Composition for improving mild cognitive impairment, and method for improving mild cognitive impairment using the composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10136669B2 (en) | Method for decreasing visceral fat or increasing energy consumption | |
| EP2050444B1 (en) | Fatigue-reducing agent | |
| JPH0920660A (en) | Stress-resistant composition | |
| US11260066B2 (en) | Inhibiting reduction of lean body mass and inhibiting accumulation of liver fat by administering allulose | |
| US20160367529A1 (en) | Debility preventative | |
| JP5922863B2 (en) | Motor function improver | |
| JP5687423B2 (en) | Alcohol fatigue improver | |
| JP2011132174A (en) | Endurance improver | |
| JP2939301B2 (en) | Oral composition | |
| JP2005225874A (en) | Iron supplement and utilization of the same | |
| JPH0797323A (en) | Iron absorption promoter | |
| JPWO2017142052A1 (en) | Amino acid-containing composition | |
| EP1733631A1 (en) | Food composition having antistress effect | |
| AU692903B2 (en) | Hemopoietic function-stimulating agent | |
| JPH0549444A (en) | Food for improvement of stamina | |
| JP2005097162A (en) | Anti-fatigue composition containing glutamine peptide | |
| JP3669988B2 (en) | Zinc-containing food | |
| JPH0881372A (en) | Preventive/therapeutic agent for medical symptom due to decrease in erytherocyte number | |
| JP6225199B2 (en) | Motor function improver | |
| JPH0881371A (en) | Hematopoietic function promoter | |
| KR20170069462A (en) | Health care food of composition comprising the extract material in Ginkgo biloba and Plantago ovata | |
| JP7787292B2 (en) | Composition for inhibiting cortisol production | |
| JP2019156834A (en) | Trait improver | |
| JP2007031403A (en) | Lactic acid production inhibitor | |
| KR20260025561A (en) | Pharmaceutical composition for treating liver disease and improving insulin resistance and method for preparing the pharmaceutical composition |